Patient response to a therapeutic or biosimilar is both a key indicator for analysing a drug’s suitability for market approval and for directing a patient’s therapy pathway. One such solution to assessing patient response is with the use of a complementary near-patient test, also known as a point-of-care (POC) test.
To achieve patient-centric growth ambitions, therapeutics need to fill a gap in the market, or meet or exceed market expectations. Here is how near-patient testing can meet this requirement:
Monitoring a patient’s response in order to direct a patient’s therapy pathway, or using a point-of-care approach to allow early diagnosis will inevitably create different testing scenarios and requirements, which can create pros and cons for both patient and clinician.
For example, there may be a requirement to monitor multiple drug activity markers, patients may need regular testing or a patient’s round trip to a clinic for routine testing could be lengthy and costly.
The following capabilities highlights how lateral flow technology can cope with various testing scenarios.
Abingdon Health specialises in the development, manufacture and commercialisation of qualitative, semi- and fully-quantitative near-patient testing solutions.
As we have launched our own blood cancer test and already work with key global pharmaceutical companies, Abingdon Health’s experience offers companies a de-risked approach to introducing a near-patient testing solution for pharma.
Our services and assistance include:
Download a copy of our brochure to see how Abingdon Health can aid the development of a near-patient testing solution to help your therapeutic or biosimilar standout from the crowd.
Topics covered in the brochure include: